Education
About Us
Working with TipRanks
Follow Us
3SBio (HK:1530)
:1530
1530 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$5.47 - HK$13.98
Previous CloseN/A
Volume7.16M
Average Volume (3M)53.09M
Market Cap
$31.22B
Enterprise ValueHK$16.47B
Total Cash (Recent Filing)¥2.69B
Total Debt (Recent Filing)¥4.84B
Price to Earnings (P/E)14.3
Beta0.81
Next Earnings
Aug 20, 2025EPS Estimate
0.55Next Dividend Ex-Date
Jul 21, 2025Dividend Yield3.29%
Share Statistics
EPS (TTM)0.94
Shares Outstanding2,397,895,000
10 Day Avg. Volume36,705,479
30 Day Avg. Volume53,088,213
Financial Highlights & Ratios
PEG Ratio0.45
Price to Book (P/B)N/A
Price to Sales (P/S)2.80
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$11.41Price Target Upside-12.40% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
3SBio News
PremiumCompany Announcements
3SBio’s 707 Injection Receives Breakthrough Therapy Designation in China
PremiumCompany Announcements
3SBio, Inc. Reports Strong Financial Growth in 2024
PremiumCompany Announcements
3SBio Announces Strong Financial Results for 2024
PremiumCompany Announcements
3SBio Announces Final Dividend for 2024
PremiumCompany Announcements
3SBio Partners with Duality Biologics for HER2 ADC Drug CommercializationPremiumCompany Announcements
3SBio Cancels Treasury Shares and Relocates Office---
Bulls Say, Bears Say
Bulls Say
Financial Performance3SBio delivered a strong performance with revenue increasing 16.5% to RMB9.1bn, driven by the robust growth of TPIAO, Mandi, and other products.
Pipeline Development3SBio has expanded its pipeline through strategic in-licensing, acquiring four key assets, including Paclitaxel Oral Solution which has received NMPA approval.
Product GrowthTPIAO's sales increased 20.4% to RMB5.1bn, becoming the leading drug in China's thrombocytopenia treatment market, with stable pricing and increasing penetration.
Bears Say
Market Expectations2H24 sales were 3% ahead of Morgan Stanley estimates and 5% above VA consensus, thanks to the strength of TPIAO and Mandi.
Strategic Expansion3SBio seeks to continue to look out for in-licensing opportunities to strengthen its portfolio mix.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
3.85%
Mutual Funds
― Other Institutional Investors
92.93% Public Companies and
Individual Investors
1530 FAQ
What was 3SBio’s price range in the past 12 months?
3SBio lowest stock price was HK$5.47 and its highest was HK$13.98 in the past 12 months.
What is 3SBio’s market cap?
3SBio’s market cap is $31.22B.
When is 3SBio’s upcoming earnings report date?
3SBio’s upcoming earnings report date is Aug 20, 2025 which is in 115 days.
How were 3SBio’s earnings last quarter?
3SBio released its earnings results on Mar 25, 2025. The company reported HK$0.44 earnings per share for the quarter, missing the consensus estimate of HK$0.456 by -HK$0.016.
Is 3SBio overvalued?
According to Wall Street analysts 3SBio’s price is currently Overvalued.
Does 3SBio pay dividends?
3SBio pays a Annually dividend of HK$0.25 which represents an annual dividend yield of 3.29%. See more information on 3SBio dividends here
What is 3SBio’s EPS estimate?
3SBio’s EPS estimate is 0.55.
How many shares outstanding does 3SBio have?
3SBio has 2,397,895,000 shares outstanding.
What happened to 3SBio’s price movement after its last earnings report?
3SBio reported an EPS of HK$0.44 in its last earnings report, missing expectations of HK$0.456. Following the earnings report the stock price went down -7.613%.
Which hedge fund is a major shareholder of 3SBio?
Currently, no hedge funds are holding shares in HK:1530
---
3SBio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.41 (-12.40% Downside)
$11.41 (-12.40% Downside)
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
25.48%
12-Months-Change
Fundamentals
Return on Equity
14.19%
Trailing 12-Months
Asset Growth
-0.42%
Trailing 12-Months
Company Description
3SBio
3SBio Inc. is a leading biopharmaceutical company in China, specializing in the research, development, manufacturing, and marketing of biopharmaceutical products. The company primarily focuses on therapeutic areas such as oncology, nephrology, and auto-immune diseases. Its core products include recombinant human erythropoietin (rhEPO) and other innovative biologics, which are significant in treating anemia in cancer patients undergoing chemotherapy and patients with chronic kidney disease.
---
1530 Stock 12 Month Forecast
Average Price Target
HK$11.41
▼(-12.40% Downside)
Technical Analysis
Ping An Insurance Company of China
―
Sino Biopharmaceutical
―
China Resources Pharmaceutical Group Ltd.
―
Livzon Pharmaceutical Group
―
CSPC Pharmaceutical Group
―
Best Analysts Covering 1530
1 Year
1 Year Success Rate
1/2 ratings generated profit
1 Year Average Return
+15.25%
reiterated a buy rating last month
Copying Jill Wu's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +15.25% per trade.
---